An interventional study of Nyaditum resae® and Mannitol in Tuberculosis, sponsored by University of Stellenbosch. Active, not recruiting at 2 sites in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by University of Stellenbosch · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 210 studies in Tuberculosis with a site in South Africa — 21 open to participants now, 35 under way, 8 of them phase 3. Tuberculosis · South Africa.
Among the 210 studies in Tuberculosis with a site in South Africa, this one is the 144th largest by enrollment of the 176 interventional ones that give a count, is one of 21 that started in 2019, is one of 41 with no phase, reaches primary completion later than 17 of the 34 other live ones, and was the 128th registered.
1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.
Browse Tuberculosis studies →21 of the 210 studies in Tuberculosis with a site in South Africa are open now. Recruiting first, the newest first:
University College, London · Sites in South Africa, Pakistan, Zimbabwe
Ages 16+
North-West University, South Africa · Sites in South Africa
Ages 18–45
Global Alliance for TB Drug Development · Sites in South Africa, Tanzania
Ages 18–65
TASK Applied Science · Sites in South Africa
Ages 18–65
Johns Hopkins University · Sites in South Africa, India, Indonesia and 4 more countries
Ages 0 days–9 yrs
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
210 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 86 · Phase 3 30 · Phase 4 9
First in 2000; this study’s year is marked. 21 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 150 across 822 interventional studies indexed under Tuberculosis.
Median enrollment 214 across the 176 interventional studies, 770 across the 34 observational. Of the 161 that completed or were terminated, 64 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 210 have an industry lead sponsor. The 10 most frequent:
University of Stellenbosch is the lead sponsor of 35 studies on the registry; 4 are open to participants now.
University of Stellenbosch has 9 studies filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Tuberculosis with a site in South Africa that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06253715Phase 3Johns Hopkins UniversityShortened Regimen for Drug-susceptible TB in Children | 2027-09-30 |
| NCT06050356Statens Serum InstitutFirst-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b | 2026-12 |
| NCT03851159University of StellenboschNyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota | 2026-12-31 |
| NCT05842161Massachusetts General HospitalSouth Africa Smoking Cessation and Engagement in HIV/TB Care Care | 2027-05-01 |
| NCT07672405Global Alliance for TB Drug DevelopmentSorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB | 2027-05-28 |
Add all 9 to your calendar (.ics) → With an account.
Among the 210 studies in Tuberculosis with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be the first study to evaluate the use of Nyaditum resae® as a potential agent for reducing antibiotic-associated gut dysbiosis in patients with drug-susceptible TB, and potentially improving clinical and microbiological markers of outcome
About one tenth of the 1.7 billion individuals infected with Mycobacterium tuberculosis (Mtb) will progress to active tuberculosis (TB). This probability increases in people with human immunodeficiency virus (HIV) and other risk co-morbidities such as malnutrition, diabetes and substance abuse. Chronic microbial colonisation with unrelated bacteria are associated with TB pathogenesis (e.g., mice colonised with Helicobacter hepaticus exhibit poor control of TB), indicating that the gut microbiota may modulate progression to active TB. Furthermore, first-line TB treatment (Isoniazid, Rifampicin, Ethambutol, Pyrazinamide; HREZ) depletes gut commensal bacteria (Ruminococcus, Coprococcus and Bifidobacterium) with immunomodulatory roles [interleukin (IL)-1, interferon (IFN)-γ and Th17 responses, respectively).
Recent work identified heat-killed Mycobacterium manresensis (hkMm), a harmless member of the fortuitum complex naturally found in drinking water, as a promising candidate for reducing the risk of active TB. Mtb-infected mice treated with hkMm had significantly reduced lung pathology (fewer and smaller lesions,) bacillary load and proinflammatory cytokines (TNF-α, IFN-γ, IL-6, and IL-17) compared to untreated control mice, and in mice receiving hkMm with HREZ, survival rates were significantly increased. Moreover, mice treated with hkMm had increased microbial diversity and an altered gut microbial composition relative to untreated mice. This could prove beneficial for TB patients during prolonged antibiotic treatment as supplementation with hkMm may help protect gut microbiota, and potentially improve clinical outcome.
In individuals with and without latent M. tuberculosis infection, two weeks of daily oral doses of Nyaditum resae® (a preparation of hkMm approved as a food supplement by Manremyc) demonstrated enhanced effector and memory specific regulatory T-cell responses. Similar clinical trials with Nyaditum resae® are currently being done in paediatrics (NCT02581579) and close contacts of active TB cases in Tbilisi, Georgia (NCT02897180; 2017-2023). The probiotic is also being registered as a food supplement in several countries.
In the proposed study, the efficacy of Nyaditum resae® in reducing antibiotic-associated gut dysbiosis and disease progression in patients with active TB will be tested. To do this, the investigators will assess changes in the microbiota during treatment (with or without Nyaditum resae® supplementation) and attempt to identify genera associated with a favourable or unfavourable treatment outcome in TB patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV-negative patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
Other: Mannitol
HIV-negative patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
Dietary Supplement: Nyaditum resae®
HIV-positive patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
Other: Mannitol
HIV-positive patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
Dietary Supplement: Nyaditum resae®
Heat-killed Mycobacterium manresensis
Placebo
Gut microbiome composition in placebo versus experimental arm
Gut microbial composition determined by next-generation sequencing of bacterial DNA in stool
Time frame: Up to 18 months
Cytokine and cluster of differentiation (CD)4+ T-cell response in placebo versus experimental arm
Cytokines responses profiled using commercial human cytokine panel, and T-cell responses characterised by flow cytometry on isolated peripheral blood mononuclear cells
Time frame: Up to 18 months
Time to sputum conversion and reduction in bacillary load
Culture used to assess sputum conversion and bacillary load
Time frame: Up to 6 months
Started May 2019 (actual). Primary completion is estimated for Dec 2026, 91 months after the start.
Of 169 non-industry interventional studies with no phase under Tuberculosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's planned 91 months is above that.
Counting every sponsor, half of 171 studies reached it within 25 months; a quarter within 14 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Stellenbosch